Home / Going-concern warnings / Citius Pharmaceuticals, Inc.
Filed 2025-05-14 路 Form 10-Q 路 Accession 0001213900-25-043360 nano
Price before filing: $0.7869 (2025-05-13 close, split/dividend-adjusted)
Market cap at flag: $10.3M (2025-05-14) 路 Latest: $12.0M (2026-10-16)
| Window | CTXR | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | +11.1% | +1.7% | +9.4% | 2025-06-13 |
| 90 days | +65.2% | +9.8% | +55.4% | 2025-08-12 |
| 180 days | +62.7% | +16.8% | +45.9% | 2025-11-10 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"Our independent registered public accounting firm's report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2025-03-31)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Newsletter delivered by beehiiv. See our privacy policy.